EP2334302B1 - Les formes posologiques pour les principes actifs qui sont faiblement ionisables - Google Patents

Les formes posologiques pour les principes actifs qui sont faiblement ionisables

Info

Publication number: EP2334302B1
Authority: EP; European Patent Office
Prior art keywords: dosage forms; ionizable compounds; weakly ionizable; weakly; compounds
Prior art date: 2008-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn - After Issue

Application number

EP09792369.2A

Other languages

German (de)

English (en)

Other versions

EP2334302A2 (fr

Inventor

Vikas Agarwal

Sami M Nazzal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cima Labs Inc

Original Assignee

Cima Labs Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-09

Filing date

2009-09-09

Publication date

2018-03-21

2009-09-09 Application filed by Cima Labs Inc filed Critical Cima Labs Inc

2011-06-22 Publication of EP2334302A2 publication Critical patent/EP2334302A2/fr

2018-03-21 Application granted granted Critical

2018-03-21 Publication of EP2334302B1 publication Critical patent/EP2334302B1/fr

Status Withdrawn - After Issue legal-status Critical Current

2029-09-09 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 title 1
239000002552 dosage form Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP09792369.2A 2008-09-09 2009-09-09 Les formes posologiques pour les principes actifs qui sont faiblement ionisables Withdrawn - After Issue EP2334302B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9549308P	2008-09-09	2008-09-09
US16199209P	2009-03-20	2009-03-20
PCT/US2009/056362 WO2010030667A2 (fr)	2008-09-09	2009-09-09	Forme galénique pour composés faiblement ionisables

Publications (2)

Publication Number	Publication Date
EP2334302A2 EP2334302A2 (fr)	2011-06-22
EP2334302B1 true EP2334302B1 (fr)	2018-03-21

Family

ID=41667166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09792369.2A Withdrawn - After Issue EP2334302B1 (fr)	2008-09-09	2009-09-09	Les formes posologiques pour les principes actifs qui sont faiblement ionisables

Country Status (5)

Country	Link
EP (1)	EP2334302B1 (fr)
JP (1)	JP5661630B2 (fr)
CA (1)	CA2735660C (fr)
MX (1)	MX340669B (fr)
WO (1)	WO2010030667A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2981258T (pt)	2013-04-05	2020-10-19	Scpharmaceuticals Inc	Formulações farmacêuticas para administração subcutânea de furosemida
CN108295264A (zh) *	2018-03-28	2018-07-20	五邑大学	聚乙烯吡咯烷酮k12的应用
ES3041602T3 (en)	2018-12-10	2025-11-13	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en)	2019-01-04	2022-02-15	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en)	2019-01-04	2025-08-26	Sq Innovation Ag	Pharmaceutical compositions of torsemide and uses thereof
PH12021551811A1 (en)	2019-01-31	2022-03-21	Scpharmaceuticals Inc	Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613332B1 (en) *	1991-06-21	2003-09-02	The University Of Cincinnati	Oral administration of therapeutic proteins
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
DE69942205D1 (de) *	1998-08-13	2010-05-12	Cima Labs Inc	Microemulsionen als feste dosisformen zur oralen verabreichung
US6228400B1 (en) *	1999-09-28	2001-05-08	Carlsbad Technology, Inc.	Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
AU1548001A (en) *	1999-11-24	2001-06-04	Wakamoto Pharmaceutical Co., Ltd.	Ophthalmic aqueous preparation
JP5684440B2 (ja) *	2001-02-23	2015-03-11	シーマ・ラブス、インコーポレイテッド	組成物および固形製剤
DE102004021281A1 (de) *	2004-04-29	2005-11-24	Boehringer Ingelheim Vetmedica Gmbh	Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin

2009
- 2009-09-09 EP EP09792369.2A patent/EP2334302B1/fr not_active Withdrawn - After Issue
- 2009-09-09 WO PCT/US2009/056362 patent/WO2010030667A2/fr not_active Ceased
- 2009-09-09 JP JP2011526303A patent/JP5661630B2/ja not_active Expired - Fee Related
- 2009-09-09 MX MX2011002084A patent/MX340669B/es active IP Right Grant
- 2009-09-09 CA CA2735660A patent/CA2735660C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2010030667A3 (fr)	2010-07-22
JP5661630B2 (ja)	2015-01-28
WO2010030667A2 (fr)	2010-03-18
MX340669B (es)	2016-07-20
MX2011002084A (es)	2011-03-29
JP2012502065A (ja)	2012-01-26
CA2735660C (fr)	2017-05-30
CA2735660A1 (fr)	2010-03-18
EP2334302A2 (fr)	2011-06-22

Legal Events

Date	Code	Title	Description
2011-05-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-06-22	17P	Request for examination filed	Effective date: 20110411
2011-06-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2011-06-22	AX	Request for extension of the european patent	Extension state: AL BA RS
2012-07-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1158980 Country of ref document: HK
2016-11-09	17Q	First examination report despatched	Effective date: 20161007
2017-10-10	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2017-11-08	INTG	Intention to grant announced	Effective date: 20171011
2018-02-12	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-02-16	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-03-02	PUAC	Information related to the publication of a b1 document modified or deleted	Free format text: ORIGINAL CODE: 0009299EPPU
2018-03-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2018-03-21	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2018-03-21	AX	Request for extension of the european patent	Extension state: AL BA RS
2018-03-21	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-03-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: PK Free format text: DIE ERTEILUNG WURDE VOM EPA WIDERRUFEN.
2018-04-04	DB1	B1 document deleted	Effective date: 20180302
2018-04-11	18W	Application withdrawn	Effective date: 20180222
2018-04-11	REG	Reference to a national code	Ref country code: LU Ref legal event code: HK Effective date: 20180328
2018-04-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180415
2018-04-18	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-04-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602009051381 Country of ref document: DE
2018-05-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R107 Ref document number: 602009051381 Country of ref document: DE
2018-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REZ Ref document number: 980352 Country of ref document: AT Kind code of ref document: T Effective date: 20180321
2019-03-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PK Free format text: DAS LOESCHDATUM WURDE ERGAENZT / LE CHAMP DATE DE RADIATION A ETE COMPLETE / LA DATA DI CANCELLAZIONE E STATA COMPLETATA

Publication	Publication Date	Title
ZA201104336B (en)	2016-10-26	Pharmaceutical compounds
GB0816372D0 (en)	2008-10-15	Pharmaceutical compounds
GB0820819D0 (en)	2008-12-24	Pharmaceutical compounds
GB0801416D0 (en)	2008-03-05	Pharmaceutical compounds
ZA201006029B (en)	2011-05-25	Pharmaceutical dosage form
IL209895A0 (en)	2011-02-28	Compounds for treating beta-amyloidoses
IL200020A0 (en)	2010-04-15	Dosage regimen for comt inhibitors
GB0816371D0 (en)	2008-10-15	Pharmaceutical compounds
GB0813740D0 (en)	2008-09-03	Therapeutic compounds
GB0806794D0 (en)	2008-05-14	Therapeutic compounds
GB0804755D0 (en)	2008-04-16	Therapeutic compounds
GB0812969D0 (en)	2008-08-20	Pharmaceutical compounds
ZA200903858B (en)	2013-10-30	Pharmaceutical dosage form
PT2271618E (pt)	2014-07-28	Compostos farmacêuticos
GB0816370D0 (en)	2008-10-15	Pharmaceutical compounds
GB0810857D0 (en)	2008-07-23	Pharmaceutical compounds
EP2285385A4 (fr)	2013-01-16	Composés à base d'arnsi pour inhiber nrf2
EP2334302B1 (fr)	2018-03-21	Les formes posologiques pour les principes actifs qui sont faiblement ionisables
EP2265260A4 (fr)	2013-07-03	Forme pharmaceutique solide traitant les céphalées
ZA201100163B (en)	2011-09-28	Unit dosage of apadenoson
PL2519233T3 (pl)	2015-06-30	Kompozycja farmaceutyczna do leczenia uzależnienia od alkoholi
GB0908905D0 (en)	2009-07-01	Pharmaceutical compounds
HK1158980A (en)	2012-07-27	Dosage forms for weakly ionizable compounds
EP2276769A4 (fr)	2011-08-17	Nouveaux composés peptidomimétiques
GB0802576D0 (en)	2008-03-19	Dosage form